Collaboration provides Laurus access to Willow's AI-driven bioengineering platform

通过合作，Laurus可以访问Willow的人工智能驱动的生物工程平台

The strategic alliance includes an initial seven high-value advanced intermediates and active pharmaceutical ingredients, including Willow's corticosteroid programs

该战略联盟包括最初的七种高价值高级中间体和活性药物成分，包括Willow的皮质类固醇计划

The agreement with Laurus is the largest collaboration agreement Willow has signed to date

与Laurus的协议是Willow迄今为止签署的最大的合作协议

SUNNYVALE, Calif., May 30, 2024 /PRNewswire/ - Willow Biosciences Inc. ('Willow') (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable ingredients, announces a multi-product development and licensing partnership with Laurus Labs ('Laurus') (Bombay Stock Exchange Code: 540222; LAURUSLABS-IN: National Stock Exchange of India), a leading research-driven pharmaceutical and biotechnology company with a $3.9 billion market cap that serves global pharmaceutical companies and offers CDMO services.

加利福尼亚州桑尼维尔，2024年5月30日/PRNewswire/-Willow Biosciences Inc.（“Willow”）（TSX:WLLW）（OTCQB:CANSF）是一家领先的生物技术公司，专注于彻底改变纯、一致和可持续成分的工业制造，宣布与Laurus Labs（“Laurus”）（孟买证券交易所代码：540222；LAURUSLABS-IN：印度国家证券交易所）建立多产品开发和许可合作关系，Laurus Labs-IN是一家领先的研究驱动型制药和生物技术公司，市值39亿美元，为全球制药公司提供CDMO服务。

Laurus has commercialised 80+ products since its inception. Laurus has nine manufacturing facilities including fermentation capabilities..

自成立以来，Laurus已将80多种产品商业化。Laurus拥有9个生产设施，包括发酵能力。。

Through this partnership, Willow will leverage its AI-driven technology platform and extensive experience in enzyme, strain, and process engineering to deliver biobased processes for high-value Active Pharmaceutical Ingredients (APIs) with existing markets, including Willow's BioOxiTM-based corticosteroid processes, for large scale manufacturing, sales, and distribution at Laurus.

通过这一合作关系，Willow将利用其人工智能驱动的技术平台以及在酶、菌株和工艺工程方面的丰富经验，在现有市场上为高价值活性药物成分（API）提供生物基工艺，包括Willow基于BioOxiTM的皮质类固醇工艺，以在Laurus进行大规模制造、销售和分销。

Willow and Laurus expect these first programs to reach commercial manufacture in 2025..

Willow和Laurus预计这些首批项目将于2025年实现商业制造。。

Under the terms of the collaboration, Willow expects to earn significant annual revenues in research & development and royalties, including $4.0 million in guaranteed research & development payments in year one. Upon commercialization of the APIs, Willow will receive an annual royalty based on worldwide sales..

根据合作条款，Willow预计将在研发和版税方面获得可观的年收入，其中包括第一年400万美元的担保研发费用。API商业化后，Willow将根据全球销售额获得年度版税。。

Laurus recognized the need to employ more sustainable methods to manufacture its APIs with reduced cost and less waste and thus, identified Willow's expertise and, specifically, its AI-driven BioOxi platform, for developing transformative bioprocesses to key APIs. This new partnership will start with the continued optimization and scaling of Willow's BioOxi platform, along with development of new processes for targets within Laurus' API and other ingredient portfolios..

Laurus认识到需要采用更可持续的方法以降低成本和减少浪费来制造其API，因此，确定了Willow的专业知识，特别是其AI驱动的BioOxi平台，用于开发关键API的变革性生物过程。这一新的合作伙伴关系将从继续优化和扩展Willow的BioOxi平台开始，同时为Laurus API和其他成分组合中的目标开发新流程。。

Willow's BioOxi biological hydroxylation platform solves for selective C-H hydroxylation at industrial scale – often referred to as one of the 'Holy Grails' of chemistry. BioOxi-enabled biomanufacturing of ingredients can remove multiple chemical steps and significantly reduce cost and resources.

Willow的BioOxi生物羟基化平台解决了工业规模的选择性C-H羟基化问题，通常被称为化学的“圣杯”之一。基于BioOxi的成分生物制造可以去除多个化学步骤，并显着降低成本和资源。

'We are excited to be partnering with Laurus Labs, one of the most respected and established pharmaceutical ingredient manufacturers in the world. This strategic partnership is the culmination of Willow's new focus on pharmaceutical ingredients and investment over the past two years,' said Dr. Chris Savile, Willow's President & CEO.

“我们很高兴能与Laurus Labs合作，Laurus Labs是世界上最受尊重和最成熟的药物成分制造商之一。Willow总裁兼首席执行官克里斯·萨维尔（ChrisSavile）博士说，这一战略合作关系是Willow过去两年对药物成分和投资的新关注的高潮。

'We are proud our technology platform is being integrated with Laurus to support their commercialization of more sustainable, cost-effective products.'.

“我们很自豪，我们的技术平台正在与Laurus集成，以支持其更可持续，更具成本效益的产品的商业化。”。

Commenting on the collaboration partnership, CEO of Laurus Labs Dr. Satyanarayana Chava said, 'Willow has demonstrated through its bioengineering technology platform a unique capability to significantly reduce the cost of API production while enabling greater product availability. We look forward to a long and successful partnership, which we believe will further strengthen Laurus' strong reputation for market innovation.'.

Laurus Labs首席执行官Satyanarayana Chava博士在评论合作伙伴关系时说，“Willow通过其生物工程技术平台展示了一种独特的能力，可以显着降低API生产成本，同时提高产品可用性。我们期待着长期而成功的合作关系，我们相信这将进一步巩固Laurus在市场创新方面的良好声誉。

With its largest agreement to-date, this multi-product agreement adds both near-term R&D and long-term commercial upside to Willow's already robust and growing pipeline of commercial opportunities in food, pharmaceuticals, and agriculture.

凭借迄今为止最大规模的协议，这项多产品协议为Willow在食品、制药和农业领域已经强大且不断增长的商业机会渠道增加了近期研发和长期商业优势。

About Willow Biosciences Inc.

关于Willow Biosciences Inc。

Willow develops and produces precision fermented functional ingredients for the health and wellness, food and beverage and personal care markets. Willow's FutureGrown™ and BioOxi™ platforms enable large-scale production with sustainability at its core. Willow's R&D team has a proven track record of developing and commercializing bio-based manufacturing processes and products to benefit our B2B partners and their customers.

Willow为健康和保健、食品和饮料以及个人护理市场开发和生产精密发酵功能成分。Willow的FutureGrowth™和BioOxi™平台以可持续性为核心实现大规模生产。Willow的研发团队在开发和商业化基于生物的制造工艺和产品方面有着良好的记录，以使我们的B2B合作伙伴及其客户受益。

For more information, or to view Willow's updated corporate presentation, visit www.willowbio.com..

欲了解更多信息，或查看Willow更新的公司演示文稿，请访问www.willowbio.com。。

FutureGrown™ and BioOxi™ are registered trademarks of Willow Biosciences Inc. All other trademarks are trademarks of their respective holders.

FutureGrowth™和BioOxi™是Willow Biosciences Inc.的注册商标。所有其他商标均为其各自持有人的商标。

About Laurus Labs

关于Laurus实验室

Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company with an aim to improve the quality of life for millions of people around the world. Laurus has a global leadership position in select APIs including anti-retroviral, oncology drugs (incl High Potent APIs), Cardiovascular, and Gastro therapeutics.

Laurus Labs成立于2005年，是一家以研究为导向的制药和生物技术公司，旨在提高全世界数百万人的生活质量。Laurus在包括抗逆转录病毒药物、肿瘤药物（包括高效API）、心血管药物和胃治疗药物在内的精选API领域拥有全球领先地位。

Laurus also offers integrated Contract Development and Manufacturing Organization (CDMO) services to Global Innovators from Clinical phase drug development to commercial manufacturing. Laurus is passionate about continuous technological advances for Smart and Green chemistry technologies to drive efficiencies and sustainable manufacturing backed by proven regulatory and quality foundation.

Laurus还为从临床阶段药物开发到商业制造的全球创新者提供综合合同开发和制造组织（CDMO）服务。Laurus热衷于智能和绿色化学技术的持续技术进步，以推动效率和可持续制造，并拥有成熟的监管和质量基础。

Laurus employs 6500+ people, including around 1250+ scientists at more than 11 facilities approved by global agencies USFDA, WHO-Geneva, Japan-PDMA, UK-MHRA, EMA, TGA etc. During FY2023 Laurus generated ₹ 6,041 crore in annual revenue and is listed on the BSE (Bombay Stock Exchange) and the NSE (National Stock Exchange) in India.

劳鲁斯拥有6500多名员工，其中约1250多名科学家在全球机构USFDA、WHO日内瓦、日本PDMA、UK-MHRA、EMA、TGA等批准的11个设施工作。在2023财年，劳鲁斯产生了₹ 年收入60.41亿卢比，在印度BSE（孟买证券交易所）和NSE（国家证券交易所）上市。

Laurus' proactive stance to conduct business with utmost Transparency, Integrity and Respect for environment & communities have earned it a place in Governance benchmark, consistently Certified Great Place to Work and Rated 'BBB' by leading MSCI ESG Ratings. Corporate Identification No: L24239AP2005PLC047518..

Laurus以最大程度的透明度、诚信度和对环境与社区的尊重开展业务，这一积极姿态为其赢得了治理基准的地位，一直被评为“最佳工作场所”，并被MSCI ESG评级机构评为“BBB”。企业识别号：L24239AP2005PLC047518。。

For more information visit www.lauruslabs.com.

有关更多信息，请访问www.lauruslabs.com。

Forward-Looking Statements

前瞻性声明

This news release may include forward-looking statements including opinions, assumptions, estimates and the Company's assessment of future plans, platforms and operations, and, more particularly, statements concerning: the collaboration agreement and development program with Laurus, including the ability to accommodate new programs and to expand capabilities and transition R&D programs to commercial revenue; the demand and market size potential of the synthetic ingredients industry; and the business plan of the Company, generally, including becoming a leader in precision fermentation, research and production of functional ingredients.

本新闻稿可能包括前瞻性声明，包括意见、假设、估计和公司对未来计划、平台和运营的评估，更具体地说，包括与Laurus的合作协议和发展计划，包括适应新计划和扩大能力以及将研发计划转变为商业收入的能力；合成原料行业的需求和市场规模潜力；以及公司的商业计划，一般来说，包括成为精密发酵、功能成分研究和生产的领导者。

When used in this news release, the words 'will,' 'anticipate,' 'believe,' 'estimate,' 'expect,' 'intent,' 'may,' 'project,' 'should,' and similar expressions are intended to be among the statements that identify forward-looking statements. The forward-looking statements are founded on the basis of expectations and assumptions made by the Company which include, but are not limited to: the success of Willow's strategic partnerships, including the partnership with Laurus and the development of future strategic partnerships; the financial strength of the Company; the ability of the Company to fund its business plan using cash on hand and existing resources; the market for Willow's products; the ability of the Company to obtain and retain applicable licences; the ability of the Company to obtain suitable manufacturing partners and other strategic relationships; and the successful implementation of Willow's commercialization and production strategy, generally.

在本新闻稿中使用的词语“将”、“预期”、“相信”、“估计”、“预期”、“意图”、“可能”、“项目”、“应该”以及类似的表达都是用来识别前瞻性陈述的。前瞻性陈述基于公司的期望和假设，包括但不限于：Willow战略伙伴关系的成功，包括与Laurus的伙伴关系以及未来战略伙伴关系的发展；公司的财务实力；公司利用现有现金和现有资源为其商业计划提供资金的能力；柳树产品市场；公司获得和保留适用许可证的能力；公司获得合适的制造合作伙伴和其他战略关系的能力；以及柳树商业化和生产战略的成功实施。

Forward-looking statements are subject to a wide range of risks and uncertainties, and although the Company believes that the expectations represented by such forward-looking statements a.

前瞻性陈述受到广泛的风险和不确定性的影响，尽管公司认为此类前瞻性陈述所代表的期望a。

Any financial outlook and future-oriented financial information contained in this document regarding prospective financial performance, financial position, cash balances or revenue, including the anticipated receipt of $4.0 million in guaranteed research & development payments in year one under the collaboration agreement and future annual royalties based on worldwide sales upon commercialization of APIs, is based on assumptions about future events, including economic conditions and proposed courses of action based on management's assessment of the relevant information that is currently available.

本文件中包含的有关预期财务业绩、财务状况、现金余额或收入的任何财务前景和面向未来的财务信息，包括根据合作协议在第一年预期收到400万美元的担保研发付款以及基于API商业化后全球销售额的未来年度版税，都是基于对未来事件的假设，包括经济状况和基于管理层对现有相关信息的评估而提出的行动方案。

Projected operational information contains forward-looking information and is based on a number of material assumptions and factors, as are set out above. These projections may also be considered to contain future-oriented financial information or a financial outlook. The actual results of the Company's operations for any period will likely vary from the amounts set forth in these projections and such variations may be material.

预计运营信息包含前瞻性信息，并基于上述许多重大假设和因素。这些预测也可能被认为包含面向未来的财务信息或财务展望。公司在任何时期的实际经营结果都可能与这些预测中规定的金额不同，这种变化可能是重大的。

Actual results will vary from projected results. Readers are cautioned that any such financial outlook and future-oriented financial information contained herein should not be used for purposes other than those for which it is disclosed herein..

实际结果将与预测结果不同。读者应注意，本文中包含的任何此类财务展望和面向未来的财务信息不应用于本文披露目的以外的其他目的。。

Financial information in this news release is expressed in Canadian dollars.

本新闻稿中的财务信息以加元表示。

The forward-looking statements contained in this news release are made as of the date hereof and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, except as required by applicable law. The forward-looking statements contained herein are expressly qualified by this cautionary statement..

本新闻稿中包含的前瞻性声明是在本新闻稿发布之日做出的，除适用法律要求外，公司没有义务公开更新或修改任何包含的前瞻性声明。本警示声明明确限定了本文所含的前瞻性声明。。

View original content to download multimedia:https://www.prnewswire.com/news-releases/willow-announces-multi-product-development-and-licensing-partnership-with-laurus-labs-for-manufacturing-active-pharmaceutical-ingredients-302159033.html

查看原始内容以下载多媒体：https://www.prnewswire.com/news-releases/willow-announces-multi-product-development-and-licensing-partnership-with-laurus-labs-for-manufacturing-active-pharmaceutical-ingredients-302159033.html

SOURCE Willow Biosciences Inc.

来源：Willow Biosciences Inc。

Company Codes: OTC-QX:CANSF, Toronto:WLLW, OTC-BB:CANSF, OTC-PINK:CANSF, OTCQB:CANSF

公司代码：OTC-QX:CANSF，多伦多：WLLW，OTC-BB:CANSF，OTC-PINK:CANSF，OTCQB:CANSF